StockNews.AI
BDSX
StockNews.AI
118 days

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

1. Biodesix contributed to ctMoniTR Project findings on ctDNA and treatment outcomes. 2. Strong link found between ctDNA changes and overall survival in aNSCLC patients. 3. Second phase of ctMoniTR expands analysis to other solid tumors and treatments. 4. Biodesix's technology could transform therapeutic development in oncology. 5. Advancements in ctDNA detection will be presented at AACR Annual Meeting.

8m saved
Insight
Article

FAQ

Why Bullish?

Biodesix's involvement in significant cancer research aligns with market demand for innovative diagnostics.

How important is it?

The study highlights Biodesix’s critical role in advancing cancer diagnostics, likely increasing investor confidence.

Why Long Term?

Long-term clinical benefits and revenue potential, as demonstrated by rising investment in personalized medicine.

Related Companies

BIOGILDAMGN
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology April 23, 2025 06:00 ET  | Source: Biodesix, Inc. LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (Nasdaq: BDSX), a leading diagnostics solutions company, and Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and diagnostics products, contributed to new research findings from Friends of Cancer Research’s (Friends’) ctMoniTR Project, recently published in Clinical Cancer Research (CCR). The findings demonstrate a strong association between changes in levels of circulating tumor DNA (ctDNA) and treatment outcomes, offering the potential for integration of ctDNA analysis in therapeutic development programs, and clinical cancer care. The ctMoniTR Project (ctDNA to Monitor Treatment Response) was designed to determine whether changes in levels of ctDNA predict treatment outcomes for patients. Results from the first phase of the project demonstrated a strong link between changes in ctDNA and overall survival in patients with aNSCLC treated with immune checkpoint inhibitors (published in the Journal of Clinical Oncology). The new data, from the second phase of ctMoniTR, expands the analysis to additional solid tumor types and treatment categories, including patients treated with tyrosine kinase inhibitors. Led by Friends, collaborators included Biodesix alongside organizations from industry, government, academia, and advocacy groups. Biodesix contributed data generated using Bio-Rad Droplet Digital™ PCR (ddPCR™) * technology to detect ctDNA from patient samples. “Biodesix is proud to be a partner on this important project, which has the potential to support a transformation of therapeutic development and clinical cancer care,” said Gary Pestano, PhD, Chief Development Officer at Biodesix. “The ctMoniTR Project is aligned with the mission and vision of Biodesix Development Services, as we strive to challenge the science and solutions of today, in order to evolve and adapt clinical decision-making to improve patient care and outcomes.” “We are very pleased that Droplet Digital™ PCR (ddPCR™) was selected for use within this study,” said Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories. “These collaborations and research programs are vital as we work towards establishing novel methods for molecular residual disease monitoring in oncology, supporting the advancement of scientific research and ultimately healthcare.” Beyond this specific research project, Biodesix offers ctDNA testing, using ddPCR technology, as part of its Development Services portfolio and is also exploring ctDNA in combination with proteomics to detect molecular residual disease (MRD). The latest advancements in this application will be presented at the American Association for Cancer Research (AACR) Annual Meeting, April 28th, 2025. *Droplet Digital and ddPCR are trademarks of Bio-Rad Laboratories, Inc. Media Contacts: Biodesix, Inc.Natalie St. Denis, Director Corporate Communications+1 720-925-9285Natalie.stdenis@biodesix.com Bio-Rad Laboratories, Inc.Katrina Academia, Inbound Marketing Manager+1 510-356-7909Katrina_academia@bio-rad.com Zyme Communications (Bio-Rad PR firm)Dr. Maria Spyrou +44 (0) 7707 049 640maria.spyrou@zymecommunications.com To opt out from receiving press releases from Zyme Communications, please e-mail info@zymecommunications.com. To view our privacy policy, click here. About Biodesix Biodesix, Inc. (Nasdaq: BDSX) is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics across disease states. For more information, visit biodesix.com. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com. Forward-Looking Statements This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in both Biodesix and Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q. Biodesix and Bio-Rad caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Related News